Abby Hardy, Author at BioTuesdays

Markets

HCW cuts Rexahn Pharma to neutral; PT to $3 from $23

H.C. Wainwright downgraded Rexahn Pharmaceuticals (NASDAQ:REXN) to “neutral” from “buy” and slashed its price target to $3 from $23 after a disappointing update from the company’s Phase 2a pancreatic cancer study...

August 8, 2019

Executive Moves

Hepion Pharma names renowned liver expert, Dr. Stephen Harrison, to its SAB

Stephen Harrison Dr. Stephen Harrison, a leading authority on liver diseases, has joined the scientific advisory board (SAB) of Hepion Pharmaceuticals (NASDAQ:HEPA). Dr. Harrison is a visiting professor of hepatology at...

August 7, 2019

Developments

Progenics Pharma completes enrollment in Phase 3 prostate cancer detection trial

Progenics Pharmaceuticals (NASDAQ:PGNX) completed enrollment for its Phase 3 study testing the diagnostic performance and clinical impact of 18F-DCFPyL (PyL) in men with recurrent prostate cancer. PyL, a small molecule...

August 6, 2019

Developments

FDA clears Mustang Bio IND for CAR T cell therapy

Mustang Bio (NASDAQ:MBIO) reported that the FDA approved its IND application for MB-102 for the treatment of acute myeloid leukemia (AML), blastic plasmacytoid dendritic cell neoplasm (BPDCN) and high-risk...

August 6, 2019

Developments

X4 Pharma’s mavorixafor gets EC orphan drug designation for WHIM syndrome

The European Commission (EC) granted X4 Pharmaceuticals’ (NASDAQ:XFOR) mavorixafor orphan drug designation for WHIM syndrome. WHIM stands for warts; hypogammaglobulinemia, or low antibody levels; infections; and...

August 1, 2019

Markets

Exicure to uplist to NASDAQ; prices $55-million public offering

Exicure’s (OTCQB:XCUR) common stock will begin trading on the Nasdaq Capital Market under the symbol “XCUR” at the opening of trading on July 31, 2019. Exicure also priced its public offering of 27,500,000 shares of its...

July 31, 2019

Developments

BELLUS Health enrolls first patient in Phase 2 chronic cough trial

BELLUS Health (TSX:BLU) enrolled the first patient in its Phase 2 study of BLU-5937 for the treatment of chronic cough. The study, called RELIEF, will assess the efficacy, safety, and tolerability of BLU-5937 at four...

July 31, 2019

Developments

MediBeacon inks $30-million agreement with Huadong Medicine in greater China

Closely-held MediBeacon and Huadong Medicine (SZ:000963) signed an agreement that will provide Huadong with exclusive rights to MediBeacon’s portfolio of assets in greater China. MediBeacon’s lead program is a point-of...

July 31, 2019

Developments

Hepion Pharma partners with University of Alberta’s Applied Pharmaceutical Innovation

Hepion Pharmaceuticals (NASDAQ:HEPA) has partnered with Applied Pharmaceutical Innovation (API) to expand its research capabilities and further characterize its lead candidate, CRV431. API is an independent institute...

July 31, 2019

Markets

Brookline starts Heat Biologics at buy; PT $8

Brookline Capital Markets launched coverage of Heat Biologics (NASDAQ:HTBX) with a “buy” rating and $8 price target. The stock closed at 52 cents on July 29. Heat Biologics has cell-therapy platforms called ImPACT and...

July 30, 2019

Author - Abby Hardy

HCW cuts Rexahn Pharma to neutral; PT to $3 from $23

Hepion Pharma names renowned liver expert, Dr. Stephen Harrison, to its SAB

Progenics Pharma completes enrollment in Phase 3 prostate cancer detection trial

FDA clears Mustang Bio IND for CAR T cell therapy

X4 Pharma’s mavorixafor gets EC orphan drug designation for WHIM syndrome

Exicure to uplist to NASDAQ; prices $55-million public offering

BELLUS Health enrolls first patient in Phase 2 chronic cough trial

MediBeacon inks $30-million agreement with Huadong Medicine in greater China

Hepion Pharma partners with University of Alberta’s Applied Pharmaceutical Innovation

Brookline starts Heat Biologics at buy; PT $8

Subscribe